CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF) Modifiable lifestyle factors and heart failure: A Mendelian randomization study Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus Dilated cardiomyopathy: so many cardiomyopathies! Heart Failure and Atrial Fibrillation, Like Fire and Fury The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE Primary Prevention of Heart Failure in Women Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure
|<<... 9 10 11 12 13 14 15 ...>>|

Original Research2019 May;21(5):665-675.

JOURNAL：Eur J Heart Fail. Article Link

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators. Keywords: protocol; heart failure; sodium-glucose co-transporter 2 inhibitor; type 2 diabetes mellitus

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top